For example, patient PANC-0117 had stage I pancreatic cancer at the time of surgery, with two pathogenic mutations present in the tumor (KRAS G12D and TP53 P152L) that were not detectable in the plasma sample (Table 2). This evidence concerns the gene TP53 and neoplasm.